Henry Schein Inc. (NASDAQ:HSIC) reported first-quarter results on Tuesday that came in ahead of Wall Street estimates, although the stock slipped modestly in after-hours trading.
The company’s shares edged down 0.10% following the release.
The healthcare solutions provider posted adjusted earnings per share of $1.32, surpassing the analyst consensus of $1.21 by $0.11. Revenue totaled $3.37 billion, exceeding the $3.34 billion estimate and rising 6.3% from $3.17 billion in the same period last year.
“I am pleased with our strong first quarter results that reflect continuing momentum from the second half of last year as we grow market share and expand gross margins,” said Fred Lowery, Chief Executive Officer of Henry Schein.
Performance was led by the Global Dental Distribution segment, where merchandise sales increased 9.0% and equipment sales climbed 8.6%. Global Medical Distribution posted a 1.7% gain, while Global Value-Added Services advanced 10.6%, including 7.8% organic growth.
Looking ahead, Henry Schein reaffirmed its fiscal 2026 adjusted EPS outlook of $5.23 to $5.37. The midpoint of $5.30 is slightly below the analyst consensus of $5.32.
The company also maintained its projection for total sales growth of roughly 3% to 5% and mid-single-digit growth in adjusted EBITDA compared to 2025.
Henry Schein noted that its value creation initiatives are expected to generate more than $200 million in operating income improvement over the next few years, including a $125 million run-rate by the end of 2026.
During the quarter, the company repurchased about 1.6 million shares for $125 million.